Company Q&A | Bloomage BioTechnology: Its medical terminal products in overseas markets are primarily distributed through a distributor model, with business coverage spanning Europe, the Russian-speaking region, the Americas, Southeast Asia, and other cou

Gelonghui, May 26 — An investor asked Bloomage BioTechnology on an interactive platform: Has the company engaged in any business activities involving exports or sales to European Union member states in recent years? If so, approximately what percentage of the company’s total revenue is attributable to the EU region? Furthermore, how does the company primarily conduct sales to the EU market—mainly through direct exports by its domestic entity to EU customers, via subsidiaries established in EU countries, or through third-party traders or agents who resell products into the EU market? Bloomage BioTechnology responded that the company does have export and sales operations to EU member states. In 2025, Bloomage

Gelonghui FinanceMay 26 17:20

Citi: Fundamentals of China's healthcare industry continue to improve, with Hengrui Pharma and Wuxi Apptec as top picks.

Gelonghui, May 12 | Citi issued a research report stating that the past fiscal year and the first-quarter earnings season have confirmed a continued improvement in the fundamentals of China's healthcare industry, driven by innovative drugs and CDMO (Contract Development and Manufacturing Organizations). The domestic medical technology, services, and pharmacy sectors have bottomed out. Innovation is yielding returns, with upfront payments and milestone payments from licensing deals boosting profitability, accelerating sales of innovative drugs, and CXO (Contract Research and Manufacturing Outsourcing) order volumes reaching new highs. Looking ahead, the bank anticipates a series of short-term catalysts, including ASCO 2026 data releases, sustained momentum in licensing deals, and developments following April 14 pharmaceutical updates.

Gelonghui FinanceMay 12 10:26 · Ratings

Citi: The fundamentals of China's healthcare industry continue to improve, with Wuxi Apptec (02359) among the top picks.

Citi has updated its Buy list for Hong Kong stocks, which includes: Hengrui Pharma (01276), CSPC Pharma (01093), Ascletis Pharma (01672), Innovent Bio (01801), Wuxi Apptec (02359), Wuxi Bio (02269), Ali Health (00241), MicroPort Surgical Robot (02252), Mindray Medical (300760.SZ), Aier Eye Hospital (300015.SZ), and Yifeng Pharmacy (603939.SH).

Zhitong FinanceMay 11 16:54

Bloomage Biotech (688363): Short-term adjustment, poised for long-term growth

The company released its annual report for 2025 and the first-quarter report for 2026. In 2025, the company's revenue amounted to 4.199 billion yuan, representing a year-on-year decrease of 21.82%; net profit attributable to shareholders reached 292 million yuan, reflecting a year-on-year increase of 67.59%; after deducting non-recurring items

Great Wall SecuritiesMay 8 15:47

Huaxi Biotechnology (688363): 68% year-on-year increase in net profit for 25 years; monitor progress of subsequent reforms.

The company's 2025 financial results are in line with previous forecasts and our expectations. According to the announcement, revenue amounted to RMB 4.199 billion, representing a year-on-year decrease of 21.8%; net profit attributable to shareholders reached RMB 292 million, marking a year-on-year increase of 67.6%; non-recurring net profit was RMB 1.

CICCMay 6 09:51

Huaxi Biotechnology (688363): Narrowing of Q1 2026 net profit decline; continuous strategic transformation throughout 2026

Key Investment Points: The company announced its Q1 2026 performance, which met market expectations. In Q1 2026, the company achieved operating revenue of 829 million yuan, representing a year-on-year decrease of 23.06%; net profit attributable to shareholders of the listed company amounted to 65 million yuan, showing a year-on-year decline.

Shenwan Hongyuan ResearchMay 1 07:36